Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Journey Medical CorpDERM · Entity 6273 | Director · President & CEO | April 22, 2026 | April 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Journey Medical Corp
Report date April 22, 2026 · Filed April 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 2,435,990 |
Reported balance
After 2026-04-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-22 · Grant · Acquired 49,277 · Balance 2,435,990 F1: On April 22, 2026, the reporting person was granted 49,277 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 16,426 shares on April 22, 2027, 16,426 shares on April 22, 2028 and 16,425 shares on April 22, 2029. F2: Includes restricted stock units, which vest over various time periods. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2036-04-22 | Direct | 82,915 |
Reported balance
After 2026-04-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-22 · Grant · Acquired 82,915 · Balance 82,915 F3: On April 22, 2026, the reporting person was granted 82,915 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 27,638 shares on April 22, 2027, 27,638 shares on April 22, 2028 and 27,639 shares on April 22, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 22, 2026, the reporting person was granted 49,277 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 16,426 shares on April 22, 2027, 16,426 shares on April 22, 2028 and 16,425 shares on April 22, 2029.
F2: Includes restricted stock units, which vest over various time periods.
F3: On April 22, 2026, the reporting person was granted 82,915 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 27,638 shares on April 22, 2027, 27,638 shares on April 22, 2028 and 27,639 shares on April 22, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2026 Filed Apr 24, 2026 21:27 UTC | Journey Medical Corp DERM · Entity 6273 | GrantStock Option (Right to Buy) · Derivative | 82,915 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001104659-26-048731 · tm2612721-1_4seq1.xml · derivative · entry 2 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,915 Underlying: Common Stock, $0.0001 par value · 82,915 shares Expires 2036-04-22 F3 · derivative.exercise_date: On April 22, 2026, the reporting person was granted 82,915 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 27,638 shares on April 22, 2027, 27,638 shares on April 22, 2028 and 27,639 shares on April 22, 2029. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 21:27 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 49,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-048731 · tm2612721-1_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,435,990 F1 · shares: On April 22, 2026, the reporting person was granted 49,277 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 16,426 shares on April 22, 2027, 16,426 shares on April 22, 2028 and 16,425 shares on April 22, 2029. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 01:54 UTC | Journey Medical Corp DERM · Entity 6273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,250,000 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001104659-25-083217 · tm2524441-1_4seq1.xml · derivative · entry 3 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.0001 par value · 1,250,000 shares Expires 2025-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On October 19, 2015, the reporting person was granted 1,250,000 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that vested in accordance with the following schedule: 412,500 shares on January 7, 2016, 250,000 shares on September 22, 2016, 337,500 shares on January 7, 2017 and 250,000 shares on September 22, 2017. The 1,250,000 stock options are due to expire on October 19, 2025. Accordingly, the reporting person is exercising the stock options within the 60 days prior to the expiration date. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 01:54 UTC | Journey Medical Corp DERM · Entity 6273 | Tax withholdingCommon Stock, $0.0001 par value | 10,877 | $7.47 | $81,251.19 |
DisclosureSEC source: 0001104659-25-083217 · tm2524441-1_4seq1.xml · nonDerivative · entry 2 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,386,713 Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 01:54 UTC | Journey Medical Corp DERM · Entity 6273 | Exercise / conversionCommon Stock, $0.0001 par value | 1,250,000 | $0.07 | $81,250.00 |
DisclosureSEC source: 0001104659-25-083217 · tm2524441-1_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,397,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Due to administrative error, the number of non-derivative securities beneficially owned by the reporting person was incorrectly reported as 2,397,590 instead of 1,147,590 on a Form 4 filed on June 20, 2025. This column reflects the corrected balance, as effected by the transactions reported on this Form 4. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:05 UTC | Journey Medical Corp DERM · Entity 6273 | GrantStock Option (Right to Buy) · Derivative | 82,915 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001104659-25-061149 · tm2518547-1_4seq1.xml · derivative · entry 2 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,915 Underlying: Common Stock, $0.0001 par value · 82,915 shares Expires 2035-06-17 F3 · derivative.exercise_date: On June 17, 2025, the reporting person was granted 82,915 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 27,638 shares on January 1, 2026, 27,638 shares on January 1, 2027 and 27,639 shares on January 1, 2028. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:05 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 49,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-061149 · tm2518547-1_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,397,590 F1 · shares: On June 17, 2025, the reporting person was granted 49,277 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 16,426 shares on January 1, 2026, 16,426 shares on January 1, 2027 and 16,425 shares on January 1, 2028. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| May 02, 2025 Filed May 5, 2025 21:34 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 4,834 | $6.84 | $33,064.56 |
DisclosureSEC source: 0001104659-25-044612 · tm2514029-3_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,348,313 F1 · shares: In connection with the vesting of restricted stock units which vested as of various dates, a total of 4,834 of the underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on May 2, 2025, was $6.73 to $7.05. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 11, 2025 Filed Mar 11, 2025 23:53 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 49,271 | $5.01 | $246,847.71 |
DisclosureSEC source: 0001104659-25-022655 · tm258917-1_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,003,147 F1 · shares: In connection with the vesting of restricted stock units which vested as of various dates, a total of 49,271 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 11, 2025, was $4.99 to $5.11. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 22:21 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 14,905 | $5.01 | $74,674.05 |
DisclosureSEC source: 0001104659-25-022257 · tm258781-1_4seq1.xml · nonDerivative · entry 2 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,052,418 F4 · shares: In connection with the vesting of restricted stock units which vested as of various dates, a total of 14,905 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F5 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 7, 2025, was $4.99 to $5.14. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 22:21 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 25,551 | $5.04 | $128,777.04 |
DisclosureSEC source: 0001104659-25-022257 · tm258781-1_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,067,323 F1 · shares: In connection with the vesting of restricted stock units which vested as of various dates, a total of 25,551 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 6, 2025, was $5.00 to $5.26. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 00:53 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 18,147 | $5.13 | $93,094.11 |
DisclosureSEC source: 0001104659-25-021043 · tm258375-1_4seq1.xml · nonDerivative · entry 3 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,092,874 F6 · shares: In connection with the vesting of restricted stock units which vested as of various dates, a total of 18,147 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F7 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 5, 2025, was $5.02 to $5.26. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 00:53 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 28,901 | $5.04 | $145,661.04 |
DisclosureSEC source: 0001104659-25-021043 · tm258375-1_4seq1.xml · nonDerivative · entry 2 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,111,021 F4 · shares: In connection with the vesting of restricted stock units which vested as of various dates, a total of 28,901 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F5 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 4, 2025, was $5.00 to $5.17. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, $0.0001 par value | 23,508 | $5.19 | $122,006.52 |
DisclosureSEC source: 0001104659-25-021043 · tm258375-1_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,139,922 F1 · shares: In connection with the vesting of restricted stock units which vested as of various dates, a total of 23,508 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 3, 2025, was $5.00 to $5.57. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| May 01, 2024 Filed Apr 16, 2025 23:07 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-035599 · tm2512519-2_4seq1.xml · nonDerivative · entry 2 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,353,147 F2 · shares: On May 1, 2024, the reporting person was granted 175,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 58,333 shares on May 1, 2025, 58,333 shares on May 1, 2026 and 58,334 shares on May 1, 2027. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Due to administrative error, the above transactions are being reported late. The aggregate amount of securities beneficially owned includes the delinquent transactions plus all transactions reported in Form 4s filed after the date of the delinquent transactions. Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 20:03 UTC | Journey Medical Corp DERM · Entity 6273 | PurchaseCommon Stock, $0.0001 par value | 10,000 | $3.48 | $34,790.00 |
DisclosureSEC source: 0001104659-24-038437 · tm249705-3_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,163,430 F1 · price: Reflects the weighted average purchase price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 22, 2024, was $3.41 to $3.48. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| January 03, 2024 Filed Apr 16, 2025 23:07 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-035599 · tm2512519-2_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,178,147 F1 · shares: On January 3, 2024, the reporting person was granted 175,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that vested or will vest in accordance with the following schedule: 58,333 shares on July 3, 2024, 58,333 shares on July 3, 2025 and 58,334 shares on July 3, 2026. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Due to administrative error, the above transactions are being reported late. The aggregate amount of securities beneficially owned includes the delinquent transactions plus all transactions reported in Form 4s filed after the date of the delinquent transactions. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 17:26 UTC | Journey Medical Corp DERM · Entity 6273 | PurchaseCommon Stock, par value $0.0001 per share | 26,044 | $2.52 | $65,630.88 |
DisclosureSEC source: 0001104659-23-099230 · tm2325760-2_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,153,430 F1 · price: Reflects the weighted average purchase price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on September 6, 2023, was $2.11 to $2.60. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 20:05 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, par value $0.0001 per share | 20,767 | $1.76 | $36,549.92 |
DisclosureSEC source: 0001104659-23-083828 · tm2322027-1_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,127,386 F1 · shares: In connection with the vesting of restricted stock units on July 24, 2023, a total of 20,767 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 24, 2023, was $1.76 to $1.80. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| May 17, 2023 Filed May 18, 2023 20:31 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, par value $0.0001 per share | 24,377 | $1.34 | $32,665.18 |
DisclosureSEC source: 0001104659-23-062286 · tm2316163-1_4seq1.xml · nonDerivative · entry 2 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,148,153 F1 · shares: In connection with the vesting of restricted stock units on May 16, 2023, a total of 44,377 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F4 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on May 17, 2023 was $1.20 to $1.40. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:31 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, par value $0.0001 per share | 20,000 | $1.25 | $25,000.00 |
DisclosureSEC source: 0001104659-23-062286 · tm2316163-1_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,172,530 F1 · shares: In connection with the vesting of restricted stock units on May 16, 2023, a total of 44,377 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on May 16, 2023 was $1.25 to $1.27. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 13:34 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, par value $0.0001 per share | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082286 · tm2221508-2_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,192,530 F1 · shares: On July 21, 2022, the reporting person was granted 300,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan. One-fourth of the shares will vest on each of July 21, 2023, 2024, 2025 and 2026, subject to the reporting person's continuous service with the Issuer. F2 · balance_after: Includes 742,530 restricted stock units, 300,000 of which will vest over various time periods as set forth in footnote 1, and 442,530 of which will vest in accordance with the following schedule: 147,362 shares on the fifteenth day of the eighteenth month following the closing of the Issuer's initial public offering (the "Tranche 1 Vesting Date"); 147,362 of which will vest nine months after the Tranche 1 Vesting Date (the "Tranche 2 Vesting Date"), and 147,806 of which will vest nine months after the Tranche 2 Vesting Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.